Breccia M et al. Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI). Cancer 2025;131(7):e35801. Abstract
Duan M et al. The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated myelofibrosis patients: The interim analysis of a prospective, open-label, multicenter, parallel-cohort, phase 2 study. ASH 2024;Abstract 1002.
Gagelmann N et al. Consistency of spleen and symptom reduction regardless of cytopenia in patients with myelofibrosis treated with pacritinib. Clin Lymphoma Myeloma Leuk 2024;24(11):796-803. Abstract
Gupta V et al. Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial. ASCO 2024;Abstract 6571.
Gupta V et al. Momelotinib vs ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma 2024;65(7):965-77. Abstract
Gupta V et al. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: Primary analysis of FREEDOM trial. Leuk Lymphoma 2024;65(9):1314-24. Abstract
Harrison C et al. Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis from the ongoing phase 2 Restore trial. ASH 2024;Abstract 997.
Harrison CN et al. Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib. Clin Lymphoma Myeloma Leuk 2025;25(3):199-211. Abstract
Harrison CN et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): Results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol 2024;11(10):e729-40. Abstract
Harrison CN et al. Momelotinib versus continued ruxolitinib or best available therapy in JAK inhibitor-experienced patients with myelofibrosis and anemia: Subgroup analysis of SIMPLIFY-2. Adv Ther 2024;41(9):3722-35. Abstract
Koschmieder S et al. Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: Recommendations from a global consensus group. Leukemia 2024;38(8):1831-8. Abstract
Masarova L et al. A phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib. ASH 2024;Abstract 999.
Mascarenhas J et al. Selinexor plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis: SENTRY phase 3 study design. Future Oncol 2025;21(7):807-13. Abstract
Mascarenhas JO et al. Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 483.
Mascarenhas JO et al. Imetelstat versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis relapsed or refractory to Janus kinase inhibitor in IMpactMF, a randomized, open-label, phase 3 trial. ASH 2024;Abstract 1808.1.
Mascarenhas JO et al. Results from the randomized, multicenter, global phase 3 BOREAS study: Navtemadlin versus best available therapy in JAK inhibitor relapsed/refractory myelofibrosis. ASH 2024;Abstract 1000.
Mascarenhas JO et al. Trial update from IMproveMF, an ongoing, open-label, dose-escalation and -expansion, phase 1/1B trial to evaluate the safety, pharmacokinetics, and clinical activity of the novel combination of imetelstat with ruxolitinib in patients with intermediate-1, intermediate-2, or high-risk myelofibrosis (MF). ASH 2024;Abstract 998.
Mascarenhas JO et al. Updated results from the phase 3 Manifest-2 study of pelabresib in combination with ruxolitinib for Janus kinase inhibitor–naïve patients with myelofibrosis. ASH 2024;Abstract 3178.
Palandri F et al. Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study. Cancer 2024;130(24):4257-66. Abstract
Vachhani P et al. Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia-supporting medications. ASH 2024;Abstract 4546.
Vachhani P et al. POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis who have a suboptimal response to ruxolitinib. ASH 2024;Abstract 1808.2.
Watts JM et al. Safety and efficacy of bromodomain and extra-terminal inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: A phase 1 study. ASH 2024;Abstract 658.